Literature DB >> 24296705

Prostate cancer: Dasatinib fails to improve on docetaxel for metastatic CRPC.

Robert Phillips.   

Abstract

Entities:  

Mesh:

Year:  2013        PMID: 24296705     DOI: 10.1038/nrurol.2013.283

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.

Authors:  John C Araujo; Géralyn C Trudel; Fred Saad; Andrew J Armstrong; Evan Y Yu; Joaquim Bellmunt; George Wilding; John McCaffrey; Sergio V Serrano; Vsevolod B Matveev; Eleni Efstathiou; Stephane Oudard; Michael J Morris; Bruce Sizer; Peter J Goebell; Axel Heidenreich; Johann S de Bono; Stephen Begbie; Jun H Hong; Eduardo Richardet; Enrique Gallardo; Prashni Paliwal; Susan Durham; Shinta Cheng; Christopher J Logothetis
Journal:  Lancet Oncol       Date:  2013-11-08       Impact factor: 41.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.